1 2 3 4 5 6 7 8 9

Werner J. Geldenhuys, B. Pharm, PhD Associate Professor; Associate Chairperson


121 Erma Byrd Building
PO Box 9530
Morgantown, WV 26506


Pharmaceutical Sciences; Rockefeller Neuroscience Institute

Graduate Training

PhD in Medicinal Chemistry, North-West University, South Africa; MS in Pharmaceutical Chemistry, Potchefstroom University for CHE, South Africa


Postdoctoral Associate, Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech Health Sciences Center

Associate Professor; Associate Chairperson

Research Interests

My group focuses on the identification and development of novel therapeutics which can slow down the disease progression of Parkinson’s disease. Specifically, we focus on the mitochondrial protein mitoNEET. MitoNEET is a drug target for neurodegeneration. We use both small organic compounds and peptides drugs in our group. Additionally we use nanoparticles to deliver compounds and proteins to the brain to bypass the blood-brain barrier.


Research Topics

  • Parkinson’s disease
  • Stroke
  • Alzheimer’s disease
  • Drug discovery
  • Mitochondrial dysfunction
  • Neurodegeneration

Lab Personnel + Collaborators

Recent Publications




  • Geldenhuys WJ, Guseman TL, Pienaar IS, Dluzen DE, Young JW.
    A novelbiomechanical analysis of gait changes in the MPTP mouse model of Parkinson’s
    PeerJ. 2015 Aug 11;3:e1175. doi: 10.7717/peerj.1175. eCollection 2015.
    PubMed PMID: 26339553; PubMed Central PMCID: PMC4558067.
  • Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR.
    Molecular determinants of blood-brain barrier permeation.
    Ther Deliv. 2015;6(8):961-71. doi: 10.4155/tde.15.32. Epub 2015 Aug 25.
    PubMed PMID: 26305616; PubMed Central PMCID: PMC4675962.
  • Geldenhuys WJ, Darvesh AS.
    Pharmacotherapy of Alzheimer’s disease: current and future trends.
    Expert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884.
    Epub 2014 Dec 8. Review. PubMed PMID: 25481975.
  • Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf
    CJ, Lim MH.
    Methyl Yellow: A Potential Drug Scaffold for Parkinson’s Disease.
    Chembiochem. 2014 Jul 8. doi: 10.1002/cbic.201300770. [Epub ahead of print]
    PubMed PMID: 25045125.
  • Geldenhuys WJ, Abdelmagid SM, Gallegos PJ, Safadi FF.
    Parkinson’s disease biomarker: a patent evaluation of WO2013153386.
    Expert Opin Ther Pat. 2014 Aug;24(8):947-51. doi: 10.1517/13543776.2014.931375.
    Epub 2014 Jun 25. PubMed PMID: 24962176.
  • Kumar V, Weng YC,
    Geldenhuys WJ, Wang D, Han X, Messing RO, Chou WH.
    Generation and characterization of ATP analog-specific protein kinase Cδ.
    J Biol Chem. 2015 Jan 23;290(4):1936-51. doi: 10.1074/jbc.M114.598698.
    Epub 2014 Dec 10.PubMed PMID: 25505183; PubMed Central PMCID: PMC4303651.


WVU Rockefeller Neuroscience Institute